Nanoparticle shows promise for ALS
A phase 2 study revealed a significant survival advantage with drug that targets mitochondria.
Brain implant is a potential life-changer for paralyzed patients
The minimally invasive device enables patients to carry out important activities of daily living.
Novel drug significantly reduces tics in Tourette syndrome – without side effects
Ecocipam does not lead to weight gain, anxiety, depression, or tardive dyskinesia, compared with placebo – a factor that may lead to better...
Gene therapy demonstrates modest success in genetic blindness
‘First step’ toward improvement in Leber hereditary optic neuropathy is maintained out to 4 years.
FDA advisory panel rejects new ALS drug
The FDA panel raised a number of issues with the clinical trial, including the study’s small sample size and no survival benefit at 24 weeks.
From the Journals
Surgery in CJD patients a potential risk factor for transmission
Brain implant allows fully paralyzed patient to communicate
The study shows for the first time that communication is possible in patients in a completely locked-in state and offers hope for a better quality...
New MIS-C guidance addresses diagnostic challenges, cardiac care
New updates in this third version of the American College of Rheumatology’s guidance include a recommendation for dual therapy with IVIg and...
Giant cell arteritis fast-track clinics pave way for greater ultrasound use in U.S.
Fast-track clinics are using vascular ultrasound to streamline diagnosis of giant cell arteritis, but the United States has a way to go to catch...
Expected spike in acute flaccid myelitis did not occur in 2020
COVID-19 interventions may have reduced transmission of the associated enteroviruses.
Which agent is best for neuromyelitis optica?
Researchers conducted an indirect treatment comparison on the efficacy of the three FDA-approved treatment options for adults with AQP4+ NMOSD.